anti-CD33 antibody-modified liposome

Anti-CD33 antibody-modified liposome is an engineered nanocarrier system in which a humanized or recombinant anti-CD33 antibody is chemically attached to the surface of a liposome to facilitate targeted drug delivery, primarily for the treatment of acute myeloid leukemia (AML). The CD33 antigen is highly expressed on the surface of most AML blast cells but minimally expressed on normal hematopoietic stem cells and non-hematopoietic tissues. Functionalization is typically achieved using maleimide-thiol chemistry to covalently bind the antibody to a PEGylated liposome shell. This platform enables the active targeting and co-delivery of chemotherapeutic agents such as cytarabine and daunorubicin, providing superior in-vivo therapeutic efficacy, increased drug uptake, and reduced off-target toxicity compared to non-targeted liposomal or conventional formulations. This approach aims to improve the therapeutic index of cytotoxic drugs and may offer reduced adverse effects relative to standard treatments[5]. Research and preclinical development are ongoing, with no currently approved products in this class.